Ascentage Pharma Group International (HKG:6855)
29.96
+0.10 (0.33%)
Nov 10, 2026, 4:08 PM HKT
Ascentage Pharma Group International Employees
Ascentage Pharma Group International had 828 employees as of June 30, 2026. The number of employees increased by 61 or 7.95% since the number was reported on December 31, 2025. That makes Ascentage Pharma Group International the 16,241st largest employer in the world and 1,091st in Hong Kong.
Employees
828
Change
61
Growth
7.95%
Revenue / Employee
896.02K HKD
Profits / Employee
-2.05M HKD
Market Cap
11.02B
Employees Chart
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 828 | 61 | 7.95% |
| Dec 31, 2025 | 767 | 200 | 35.27% |
| Dec 31, 2024 | 567 | -16 | -2.74% |
| Dec 31, 2023 | 583 | 3 | 0.52% |
| Dec 31, 2022 | 580 | -33 | -5.38% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Shanghai Haohai Biological Technology | 1,999 |
| Everest Medicines | 812 |
| Suzhou Ribo Life Science | 453 |
| CARsgen Therapeutics Holdings | 424 |
| HBM Holdings | 327 |
| Duality Biotherapeutics | 266 |
| CStone Pharmaceuticals | 147 |
Ascentage Pharma Group International News
- 5 days ago - Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026 - GlobeNewsWire
- 6 days ago - Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London - GlobeNewsWire
- 20 days ago - Ascentage Pharma's Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL - GlobeNewsWire
- 25 days ago - Ascentage Pharma initiated with an Outperform at William Blair - TheFly
- 27 days ago - Ascentage Pharma initiated with a Buy at Citi - TheFly
- 4 weeks ago - Ascentage Pharma initiated with an Outperform at Citizens - TheFly
- 4 weeks ago - 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead - MarketBeat
- 4 weeks ago - Ascentage Pharma price target lowered to $33 from $46 at JPMorgan - TheFly